

Amendments to claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please cancel claims 38 to 64 without prejudice or disclaimer.

Please add claims 65 to 94 as follows:

Claims 1 to 64 (canceled).

65. (new) An isolated HIV envelope protein capable of inducing the production of a cross-reactive neutralizing anti-serum against multiple strains of HIV-1 *in vitro* comprising an amino acid sequence with at least about ninety-two (92) percent sequence identity to SEQ ID NO: 1.

66. (new) The isolated HIV envelope protein of claim 65 wherein the protein comprises an amino acid sequence with at least about ninety-five (95) percent sequence identity to SEQ ID NO: 1.

67. (new) The isolated HIV envelope protein of claim 65 wherein the protein comprises an amino acid sequence with at least about ninety-eight (98) percent sequence identity to SEQ ID NO: 1.

68. (new) The isolated HIV envelope protein of claim 65 wherein the protein comprises an amino acid sequence with at least about ninety-nine (99) percent sequence identity to SEQ ID NO: 1.

69. (new) An isolated HIV envelope protein capable of inducing the production of a cross-reactive neutralizing anti-serum against multiple strains of HIV-1 *in vitro* comprising an amino acid sequence with eighty-five (85) percent sequence identity in the V3 region of SEQ ID NO: 1.

70. (new) The isolated HIV envelope protein of claim 69 wherein the protein comprises an amino acid sequence with at least about ninety (90) percent sequence identity in the V3 region of SEQ ID NO: 1.

71. (new) The isolated HIV envelope protein of claim 69 wherein the protein comprises an amino acid sequence with at least about ninety-five (95) percent sequence identity in the V3 region of SEQ ID NO: 1.

72. (new) The isolated HIV envelope protein of claim 69 wherein the protein comprises an amino acid sequence with at least about ninety-nine (99) percent sequence identity in the V3 region of SEQ ID NO: 1.

73. (new) The isolated HIV envelope protein of claim 69 wherein the V3 region comprises amino acids 13 to 25 of SEQ ID NO: 3.

74. (new) The isolated HIV envelope protein of claim 69 wherein the V3 region comprises the amino acid sequence of SEQ ID NO: 3.

75. (new) The isolated HIV envelope protein of claim 65 or 69 wherein the protein comprises a cyclic peptide.

76. (new) The isolated HIV envelope protein of claim 65 or 69 wherein the protein is at least about 95 amino acid residues in length.

77. (new) The isolated HIV envelope protein of claim 65 or 69 wherein the HIV envelope protein is recombinantly produced.

78. (new) The isolated HIV envelope protein of claim 65 or 69 wherein the protein is glycosylated at one or more amino acid residues.

79. (new) The isolated HIV envelope protein of claim 65 or 69 wherein the HIV envelope protein is synthetically produced.

80. (new) The isolated HIV envelope protein of claim 65 or 69 wherein the protein is linked to a second protein.

81. (new) The isolated HIV envelope protein of claim 80 wherein the protein is linked to the second protein by a peptide linker.

82. (new) An isolated HIV envelope protein comprising the amino acid sequence of SEQ ID
NO: 1.

83. (new) An isolated HIV envelope protein consisting of the amino acid sequence of SEQ ID
NO: 1.

84. (new) A composition comprising an isolated HIV-1 envelope protein of any one of claims 65,
69, 82 or 83 and a pharmaceutically acceptable carrier.

85. (new) The composition of claim 84 further comprising an adjuvant.

86. (new) The composition of claim 84 wherein the composition is suitable for use in humans.

87. (new) A method of generating antibodies in a mammal comprising administering the
composition of claim 84.

88. (new) A method of generating antibodies in a mammal comprising administering the isolated
HIV-1 envelope protein of claim 65 or 69.

89. (new) The method of claim 88 wherein the mammal is a human.

90. (new) The method of claim 88 wherein the antibodies produced are monoclonal.

91. (new) The method of claim 90 wherein the mammal is a mouse.

92. (new) The method of claim 90 further comprising humanizing the monoclonal antibody.

93. (new) The method of claim 88 wherein the antibodies produced are polyclonal.

94. (new) The method of claim 88 wherein the mammal is a primate.